Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
  • References (0)
  • Citations (5)
Cited By5
Published on Jan 1, 2018
Mark Avigan17
Estimated H-index: 17
(FDA: Food and Drug Administration),
Mark Avigan (FDA: Food and Drug Administration), Monica A. Muñoz3
Estimated H-index: 3
(FDA: Food and Drug Administration)
Published on May 1, 2014in Lancet Neurology 28.75
Gavin Giovannoni72
Estimated H-index: 72
(QMUL: Queen Mary University of London),
R. Gold73
Estimated H-index: 73
(RUB: Ruhr University Bochum)
+ 9 AuthorsMarianne Sweetser14
Estimated H-index: 14
(Biogen Idec)
Summary Background In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received daclizumab high-yield process (HYP) for 52 weeks. The primary aim of the SELECTION extension study was to assess the safety and immunogenicity of extended treatment with daclizumab HYP. Methods A multicentre, randomised, double-blind, 52-week extension trial was done in 74 centres in the Czech Republic, Germany, Hungary, India, Poland, Russia, Ukraine, and the UK between Feb 13, ...
Published on Mar 1, 2014in Clinical and Experimental Immunology 3.71
Paulus S. Rommer15
Estimated H-index: 15
(Medical University of Vienna),
Uwe K. Zettl39
Estimated H-index: 39
(University of Rostock)
+ 6 AuthorsOlaf Stüve47
Estimated H-index: 47
During the last two decades, treatment options for patients with multiple sclerosis (MS) have broadened tremendously. All agents that are currently approved for clinical use have potential side effects, and a careful risk–benefit evaluation is part of a decision algorithm to identify the optimal treatment choice for an individual patient. Whereas glatiramer acetate and interferon beta preparations have been used in MS for decades and have a proven safety record, more recently approved drugs appe...
Published on Jan 1, 2013
E Sinagra , Francesca Rossi2
Estimated H-index: 2
+ 3 AuthorsDario Raimondo5
Estimated H-index: 5
Introduction Multiple sclerosis is a chronic inflammatory disease of the central nervous system of autoimmune origin. During the last decades, several disease-modifying therapies have been licensed that ameliorate the course of the disease. The purpose of these DMT is to reduce inflammation, disease activity, as measured by MRI and relapse rate. However, DMT and interferons, in particular, are associated with a number of adverse reactions which include transient liver function abnormalities. The...